Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Directorate Changes

18 May 2022 07:00

RNS Number : 8511L
Alliance Pharma PLC
18 May 2022
 

 

For immediate release

18 May 2022

 

 

 

ALLIANCE PHARMA

("Alliance" or the "Group")

 

Directorate changes

 

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, in line with good corporate governance, David Cook, Alliance's Chair, will be stepping down next year, following the AGM in May 2023, after serving on the Board for nine years.

 

Jo LeCouilliard, currently a Non-Executive Director on the Board of Alliance, will become Chair following the AGM in May 2023.

 

Jo LeCouilliard joined Alliance as a Non-Executive Director on 1 January 2019. She brings over 25 years of international healthcare management experience through her career at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and the Asia Pacific Pharmaceuticals business. Jo is a Chartered Accountant and is currently a Non-Executive Director at Circassia Group plc, Indivior plc and Recordati S.p.a.

 

David Cook commented: "Alliance has developed significantly over the time I have been with the business, building an international footprint and transitioning to focus on consumer healthcare brands. I am confident that the Company has a bright future, led by an outstanding senior management team. Jo has been an invaluable Board member over the past three and a half years and we are delighted that she has agreed to chair the Board as the Company continues on its growth trajectory. I look forward to working closely with her during my remaining time at Alliance."

 

Jo LeCouilliard commented: "I am delighted to be taking on the position of Chair following next year's AGM. I have been really impressed by Alliance's strong management team and strategy over my last three and a half years on the Board. The Company has successfully executed a number of strategic consumer healthcare acquisitons and has built a solid international infrastructure. I look forward to leading the Board in taking the Company forward."

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

alliancepharma@buchanan.uk.com

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield / Duncan Monteith

 

Corporate Broking: James Black

 

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams

 

Corporate Broking: Patrick Robb

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPUWWAUPPGMM
Date   Source Headline
23rd Nov 20165:45 pmRNSExercise of Share Options
17th Nov 20165:05 pmRNSNotification of Major Interest in Shares
17th Nov 201610:40 amRNSExercise of Share Options
28th Oct 20165:13 pmRNSShare Options
28th Oct 20167:00 amRNSAppointment of Deputy CEO
5th Oct 20166:00 pmRNSExercise of Share Options
23rd Sep 20167:01 amRNSExercise of Share Options
23rd Sep 20167:00 amRNSDirector Dealings
14th Sep 20167:00 amRNSInterim Results
13th Sep 20167:00 amRNSNew Agreement for Diclectin in Europe
18th Aug 20167:00 amRNSInterim Results Analyst Meeting - Change of Time
8th Aug 20165:00 pmRNSExercise of Share Options
2nd Aug 20167:00 amRNSNotification of Interim Results
26th Jul 20167:00 amRNSExercise of Share Options
19th Jul 20167:00 amRNSHalf Year Trading Update
12th Jul 20167:00 amRNSNotification of Half Year Trading Update
25th May 201611:15 amRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
24th May 20167:00 amRNSExercise of Share Options
5th May 20161:30 pmRNSDirector Shareholding
3rd May 20167:00 amRNSExercise of Share Options
28th Apr 20167:00 amRNSAnnual Report and AGM Notice
7th Apr 20167:00 amRNSPreliminary Results
18th Mar 20167:00 amRNSNotification of Preliminary Results
3rd Mar 20167:00 amRNSHardman & Co Research Report
5th Feb 20163:57 pmRNSExercise of Share Options
22nd Jan 20163:45 pmRNSExercise of Share Options
21st Jan 20167:00 amRNSPre-Close Trading Update
12th Jan 20162:34 pmRNSNotification of Major Interest in Shares
7th Jan 20161:56 pmRNSNotification of Major Interest in Shares
23rd Dec 201512:02 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Dec 20154:40 pmRNSDirector Shareholding
18th Dec 20155:15 pmRNSNotification of Major Interest in Shares
18th Dec 20154:20 pmRNSNotification of Major Interest in Shares
18th Dec 20153:54 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th Dec 20153:39 pmRNSNotification of Major Interest in Shares
17th Dec 20153:13 pmRNSNotification of Major Interest in Shares
17th Dec 20159:00 amRNSCompletion of Acquisition and Placing
14th Dec 20154:00 pmRNSResult of General Meeting
8th Dec 20155:41 pmRNSNotification of Major Interest in Shares
7th Dec 20157:00 amRNSShare Options
3rd Dec 20152:03 pmRNSPlacing Update: Exercise of Broker's Option
2nd Dec 20158:00 amRNSSchedule 1 - Alliance Pharma Plc
26th Nov 20154:35 pmRNSInterim Dividend Timetable
26th Nov 20157:00 amRNSProposed Acquisition
23rd Nov 20154:00 pmRNSDirectorate Change
5th Nov 20157:00 amRNSSettlement Agreement
10th Sep 20157:00 amRNSInterim Dividend Timetable - Record Date
9th Sep 20157:00 amRNSInterim Results
2nd Sep 20156:01 pmRNSNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.